GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review
FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...
US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients
The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic ...
Nasdaq12d
AZN: TEZSPIRE Reduces Nasal Polyp Severity And Surgery Need In CRSwNP Patients In Phase III Trial
(RTTNews) - The Phase III WAYPOINT trial results revealed that AstraZeneca (AZN.L, AZN) and Amgen's (AMGN) TEZSPIRE (tezepelumab-ekko) significantly decreased nasal polyp severity, reduced the ...
Agence France-Presse14d
RDD Europe 2025, Co-Organized by Aptar Pharma and RDD Online, Celebrates 20 Years
Celebrating 20 years of RDD Europe and one of the largest and highly regarded international respiratory health conferences, RDD Europe 2025 will host over 500 scientists, engineers, clinicians and ...